Conference Programme

DAY 1 – Wednesday 30 th August 2023 – WELCOME FUNCTION		
18.30 – 18.35	Welcome	
	Katie Burns	
	Chair of ASCEPT NZ	
18.35 – 19.30	Registration opens. Drinks, nibbles, and networking function	

DAY 2 – Thursday 31 st August 2023 – ANNUAL SCIENTIFIC MEETING		
08.30 - 09.00	Registration opens. Tea and coffee available	
Welcome / Housekeeping		
09.00 - 09.10	Katie Burns	
Oral Communications Session 1 – Chair: Jacqui Hannam		
09.10 - 09.30	The impact of allopurinol adherence patterns on outcomes in people	
	with gout	
	Daniel Wright (A1)	
	University Of Otago	
09.30 – 09.50	The Na+ K+ ATPase as a potential target for modulating	
	neuroinflammation	
	Caitlin Oyagawa (A2)	
	University Of Auckland	
09.50 - 10.10	Investigation of the interaction of proton-pump inhibitor drugs with	
	capecitabine chemotherapy	
	Nuala Ann Helsby (A3)	
	University Of Auckland	
10.10 - 10.40	Morning Tea	
Student Presentation	ns 1 – Chair: Katie Burns	
10.40 - 11.00	Activated yet in-active; the paradoxical effect of dasatinib on	
	Lymphocyte Specific Kinase	
	Samantha Rickard (A4)	
	University Of Auckland	
11.00 - 11.20	oCOm-21 Improves Haemodynamic Function and Enhances Ca2+	
	Sensitivity by a Heme-Dependent Mechanism	
	Fergus Payne (A5)	
	University Of Otago	
11.20 - 11.40	Structure guided poly-pharmacology targeting the bacterial GHKL	
	proteins to overcome antibiotic resistance	
	Te Xiao (A6)	
	University Of Auckland	
11.40 – 12.00	The effect of alcohol consumption on blood glucose in young adults with	
	type 1 diabetes mellitus	
	Amy (Yoonseo) Chung (A7)	
	University of Otago	







12.00 – 12.20	The effect of compulsory indications in electronic prescriptions for cardiovascular medicines Lorna Pairman (A8) University Of Otago
12.20 – 13.20	Lunch
Symposium – Chair:	Jack Flanagan
13.20 – 13.50	Human brain neuropharmacology Mike Dragunow (A9) University of Auckland
13.50 – 14.20	The critical role of dimethylarginine dimethylaminohydrolase-1 (DDAH1) in modulating vasculogenic mimicry in cancer: current evidence and therapeutic opportunities Arduino Mangoni (A10) Flinders University
14.20 – 14.50	More than a Class A placebo? A randomised controlled trial of microdosed lysergic-acid diethylamide Rachael Sumner (A11) University of Auckland
14.50 – 15.10	Discussion/Question Time
15.10 – 15.40	Afternoon Tea
Oral Communication	s Session 2 – Chair: Ivan Sammut
15.40 – 16.00	Investigating clozapine transport kinetics using radiolabelled drug; a lot of work to prove we picked the wrong assay Katie Burns (A12) University Of Auckland
16.00 – 16.20	A systems overview of the clinical data environment for evaluating medicines use in NZ Hospitals Matt Doogue and Lorna Pairman (A13) University of Otago
16.20 – 16.40	Use of R-Shiny Apps to Enhance Learning of Core Concepts in Pharmacology David Reith (A14) University Of Otago
16.40 – 16.50	Comfort Break
ASCEPT-NZ AGM	
16.50 – 17.50	AGM
	Break
Conference Dinner	
18.30 onwards	My Thai Lounge

DAY 3 – Friday 1 st September 2023 – ANNUAL SCIENTIFIC MEETING		
09.00 – 09.20	Interruptive clinical decision support (CDS) alerts for improved prescribing: implications of prescriber overrides.	
	Milan Sundermann (A15)	
	University Of Otago	







09.20 - 09.40	Prescribing Systems Alerts to Support Change in Funded ACE Inhibitors
	at Canterbury Hospitals
	Kelvin Gong (A16)
	Te Whatu Ora Waitaha Canterbury
09.40 - 10.00	Untangling the paradoxical dose-exposure-response relationship for
	allopurinol
	Hailemichael Hishe (A17)
	University Of Otago
10.00 - 10.20	Characterising the inotropic mechanism of action of oCOm-21 in isolated
	cardiomyocytes
	Sam Nie (A18)
	University Of Otago
10.20 - 10.40	Chemical proteomics approaches to elucidate the cytoprotective
	mechanism of compounds in human-brain derived pericyte oxidative
	stress models
	Raahul Sharma (A19)
	University Of Auckland
10.40 - 11.10	Morning Tea
ASCEPT Guest Speake	er – Chair: Matt Doogue
11.10 - 11.40	Orphan G protein-coupled receptors: pain points and opportunities
	Nicola Smith (A20)
	UNSW Sydney
Oral Communications	s 3 – Chair: Matt Doogue
11.40 – 12.00	One inhibitor, two mechanisms? evidence for allosteric regulation of the
	lipid kinase PI3Kα
	Jack Flanagan (A21)
	University Of Auckland
12.00 – 12.20	The good and not so good of dose banding for dose individualisation
	Stephen Duffull (A22)
	Certara
12.20 – 12.30	Conference Close and Prizegiving
12.20 12.30	contention close and thize giving





